Dispense a copy of the Dear Healthcare Professional Letter with each box IMPORTANT PRESCRIBING INFORMATION: cycloSERINE Capsules | Cycloserine [Macleods Pharmaceuticals Limited] | BioPortfolio

17:46 EST 26th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Subject: Temporary importation of cycloSERINE, 250 mg capsules to address shortage

January 07, 2019

Dear Healthcare Professional,

Due to an anticipated shortage of SEROMYCIN® - cycloSERINE capsules, 250mg in the United States (U.S.) market by the end of 2018, Macleods Pharmaceuticals Limited, India (Macleods) is co-ordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of cycloSERINE capsules, 250mg for patients in the United States. Macleods has initiated temporary importation of cycloSERINE capsules, 250 mg into the United States market. This drug product is marketed globally and is manufactured in India.

At this time no other entity except Macleods is authorized by the FDA to import cycloSERINE capsules, 250 mg in the United States. FDA has not approved Macleods cycloSERINE capsules, 250 mg in the United States.

Effective immediately, and during this temporary period, Macleods will offer the following version:

 It is important to note the following: • The imported product and U.S. FDA-approved product (SEROMYCIN®) contain the same active ingredient (cycloSERINE), strength (250 mg), and dosage form (capsules).  • Please note the difference in the imported capsules’ appearance.  The imported cycloSERINE capsule is maroon-colored.  The U.S.FDA-approved SEROMYCIN® (cycloSERINE) capsule has an opaque red cap and opaque grey body and is imprinted with “CHAO” and “F04”.

• The barcode may not register accurately on the U.S. scanning systems.  Alternative procedures should be followed to assure that the correct drug product is being used and administered to individual patients.  For example, institutions should consider manually inputting the product into their systems and confirm that barcode systems do no provide incorrect information when the product is scanned. 

Please refer to the package insert for the FDA-approved cycloSERINE capsules for full prescribing information, including the Warning section for risk of CNS toxicity.

The product comparison table below highlights the differences between the FDA-approved SEROMYCIN (cycloSERINE) capsules and the imported cycloSERINE capsules.

To place an order, or if you have any questions about the information contained in this letter or the use of cycloSERINE capsules, 250 mg, please contact Macleods at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email at

To report adverse events or quality problems associated with the use of this product, please call Macleods at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email at

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

• Complete and submit the report Online: • Regular Mail or Fax: Download form call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178)

We urge you to contact our Medical Information Department at 1-888-943-3210 between the hours of 8 a.m. and 5 p.m. (ET), or email If you have any questions about the information contained in this letter or the safe and effective use of CycloSERINE capsules.


Dr Ashish Mungatiwar Executive President Medical Services Macleods Pharmaceuticals

 Comparison Table


Product Name and Description
cycloSERINE Capsules, 250mg
30 Capsules, Non-Child Resistant
Packs of 3x10
NDC 33342-462-06
U.S. FDA Approved Product
Imported Product
Seromycin (cycloSERINE) capsule, 250 mg
cycloSERINE capsule, 250 mg

Cycloserine capsules USP, 250 mg

Pack Count: 30's carton pack                             NDC  33342-462-06


Macleods Pharmaceuticals Limited

Active Ingredients


Clinical Trials [61 Associated Clinical Trials listed on BioPortfolio]

Target Engagement of D-cycloserine (DCS)

Assess the mechanism of action of d-cycloserine (DCS) to guide development of other medications working via similar molecular targets.

fMRI Study Examining Effects of D-Cycloserine in Specific Phobia

The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloseri...

RCT of CBT Combined With D-Cycloserine for Treating PTSD

The purpose of this study is to investigate if the effectiveness of cognitive-behavioral therapy for post-traumatic stress disorder can be increased by combining it with D-cycloserine (TCC...

D-cycloserine in the Management of Chronic Low Back Pain

Pre-clinical studies in rats suggest that D-cycloserine is effective in the management of chronic neuropathic pain. This pilot study will attempt to determine the effect of D-cycloserine i...

Once Weekly D-cycloserine for Schizophrenia

This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 ...

PubMed Articles [9 Associated PubMed Articles listed on BioPortfolio]

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

d-cycloserine is used to treat multidrug-resistant tuberculosis. Its efficacy, contribution in combination therapy, and best clinical dose are unclear, also data on the d-cycloserine minimum inhibitor...

D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome.

Over half of children receiving cognitive behavioral therapy (CBT) for obsessive compulsive disorder (OCD) do not fully remit. To improve response rates and enhance extinction learning, d-cycloserine ...

Ethanol withdrawal limits fear memory reactivation-induced molecular events associated with destabilization phase: Influence of d-cycloserine.

A 1-day fear memory in ethanol withdrawn (ETOH) rats is resistant to destabilization-reconsolidation process. However, d-cycloserine (DCS) reverts this disturbance. Considering that the formation of p...

Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.

Within the general nitrofuran carboxamide chemotype, chimera derivatives incorporating diversely substituted imidazoles attached via an alkylamino linker were synthesized. Antimycobacterial evaluation...

Drug Susceptibility of Non-tuberculous Strains of Isolated from Birds from Poland.

Mycobacterioses are a constant problem in backyard poultry, as well as pet birds. To date, no evidence of direct transmission of atypical bacilli between humans has been demonstrated, but it cannot be...

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record